BERLIN (EGMN) - Irinotecan significantly prolonged overall survival, compared with best supportive care in patients with advanced gastric cancer, according to results of the first randomized phase III trial investigating second-line chemotherapy in this setting. This study is potentially practice changing, as there is no established standard in this setting."Second-line chemotherapy should be considered a proven option in advanced gastric cancer," stated Dr. Peter Thuss-Patience, who presented this...